An updated expert consensus statement on catheter and surgical ablation of atrial fibrillation offered practical advice on various new tools in the field.
New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.
Edwards Lifesciences received approval for its Evoque tricuspid valve replacement system, the first transcatheter therapy approved in the US for tricuspid regurgitation.
Boston Scientific has received approval for the Farapulse Pulsed Field Ablation system for treatment of drug-refractory, recurrent paroxysmal atrial fibrillation.